Celldex Therapeutics, Inc. is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

View all →   RSSRecent Releases
Sep 30, 2014 Celldex Announces Publication of Glembatumumab Vedotin Phase 1/2 Studies in the Journal of Clinical Oncology
Sep 25, 2014 Celldex Therapeutics Initiates Pilot Study of CDX-301 in Allogeneic Hematopoietic Stem Cell Transplantation
What's New

2012 Form 10-K

More →Featured Events
Sep 8, 2014
1:25 PM ET
Morgan Stanley Healthcare Conference
Aug 6, 2014
4:30 PM ET
Celldex Therapeutics Second Quarter Financial Results
More →Upcoming Events
Details on upcoming events are not yet available.
Featured Financial Reports
Filing Date Title Type Size
Aug 7, 2014 Form 10-Q View HTML View PDF 327.9 KB Add to Briefcase
Mar 3, 2014 Form 10-K View HTML View PDF 909.7 KB Add to Briefcase
Add to Briefcase = add file to Briefcase